{"id":"NCT00411554","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)","officialTitle":"Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2007-08","completion":"2007-08","firstPosted":"2006-12-14","resultsPosted":"2009-09-25","lastUpdate":"2016-02-05"},"enrollment":319,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"],"interventions":[{"type":"DRUG","name":"sitagliptin phosphate","otherNames":["MK0431"]},{"type":"DRUG","name":"Comparator: voglibose","otherNames":["voglibose"]}],"arms":[{"label":"Sitagliptin 50 mg QD","type":"EXPERIMENTAL"},{"label":"Voglibose 0.2 mg TID","type":"ACTIVE_COMPARATOR"}],"summary":"The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Sitagliptin 50 mg QD","deltaMin":-0.7,"sd":null},{"arm":"Voglibose 0.2 mg TID","deltaMin":-0.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20590736"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Nasopharyngitis","Flatulence","Abdominal distension","Diarrhoea","Alanine aminotransferase increased"]}}